Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
24 /100
LOW RISK
Score updated Oct 24, 2026

RIGL — Rigel Pharmaceuticals, Inc. Dilution Risk Tracker

Track RIGL dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track RIGL — Get alerts when the score changes →

As of October 24, 2026, Rigel Pharmaceuticals, Inc. (RIGL) has a DilutionWatch DilutionScore of 24/100, rated LOW dilution risk. Rigel Pharmaceuticals, Inc. has a market capitalization of $899.06M, 18.68M shares outstanding, 13 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
37
💰 Cash Runway
0
📊 Float Risk
15
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for RIGL.
🔔 Track RIGL — Get forecast alerts →

Market Data

Market Cap$899.06M
Shares Outstanding18.68M
Float15.94M
Cash$95.33M
Debt$45.00M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore24/100DilutionWatch score record
Shares Outstanding18.68MVerified float table or market cache
Public Float15.94MVerified float table or market cache
Market Cap$899.06MMarket data cache
Cash Runway157.7 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 5.

Recent SEC source mix: FORM 4 5.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

RIGL SEC Filing Activity — Last 12 Months

Shares outstanding reported by RIGL on the cover page of its latest 10-K/10-Q: 18.68M as of July 30, 2026.

DilutionWatch recorded no shelf, registration or prospectus documents for RIGL in the last 12 months. Full filing list on SEC EDGAR →

FormWhat it isFilingsMost recent
8-Kcurrent report (material event)3Aug 04, 2026
10-Qquarterly report1May 05, 2026
DEF 14Aproxy statement1Apr 03, 2026
SC 13G/Aamended passive >5% holder filing2Aug 14, 2026
3initial insider ownership25Sep 03, 2026

Institutional Holdings

QoQ: ↑ 0.6% shares (2026Q1 vs prior)
13 institutional holders · 157.8K shares
#1 Quinn Opportunity Partners LLC 41.4K shares
#2 GEODE CAPITAL MANAGEMENT, LLC 39.5K shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 34.0K shares
+ 10 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest2.86M
Days to Cover11.1
% of Float17.9%
FINRA data as of Sep 30, 2026

Recent SEC Activity

Form 4 INSIDER TRANSACTION 2026-09-02
Form 4 INSIDER TRANSACTION 2026-09-02
Form 4 INSIDER TRANSACTION 2026-09-02
Form 4 INSIDER TRANSACTION 2026-09-02
Form 4 INSIDER TRANSACTION 2026-09-01
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual RIGL Dilution Snapshot

Rigel Pharmaceuticals, Inc. (RIGL) has a DilutionScore of 24/100, rated Low dilution risk. Score date: October 24, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

RIGL's DilutionScore is currently 24/100 (Low risk), with 2 score changes tracked over 89 days. The score improved from 23/100 (Low risk).

Period Score Risk Level Duration
Aug 22 – Oct 24, 202624/100LOW64 days
Aug 14 – Aug 21, 202623/100LOW7 days
Jul 27 – Aug 13, 202624/100LOW18 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

RIGL shares outstanding have increased 1.9% from 18.15M (Mar 2026) to 18.50M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 31, 202618.50M15.94M▼ 0.02%
May 30, 202618.50M15.94M▼ 0.02%
May 19, 202618.50M15.95M▼ 7.43%
May 10, 202618.50M17.23M▼ 5.32%
May 08, 202618.50M18.20M▲ 0.16%
Apr 08, 202618.48M18.17M▼ 0.06%
Mar 08, 202618.15M——
Mar 05, 202618.15M——

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track RIGL Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment RIGL files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking RIGL — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,550+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for RIGL
RIGL FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.